Treatment
S-1 clinical trials
We’re tracking 792 recruiting studies that include S-1, each written for real people, not researchers, below.
Recruiting studies
- NCT07481175RecruitingPhase 1
Testing a drug to reduce hidden HIV early after treatment start
This trial tests whether adding venetoclax, a drug that helps infected cells die, at the start of HIV treatment can lower the amount of hidden virus that stays in the body. It may help reduce the HIV reservoir.
AarhusAges 18–70 - NCT07472517RecruitingPhase 3
Obrixtamig plus standard therapy for advanced small cell lung cancer
This trial tests whether adding a new drug, obrixtamig, to the usual first treatment for extensive-stage small cell lung cancer can help people live longer or slow the cancer's growth. The usual treatment is a combination of atezolizumab, carboplatin, and etoposide.
Mobile, AlabamaAges 18 years+ - NCT07480109Recruiting
More protein while on weight-loss meds in women
This study tests if eating extra protein helps middle-aged women with overweight or obesity who are just starting a GLP-1 medication. You would eat extra protein for a few weeks while staying active as usual.
Austin, TexasAges 30–60 - NCT07476339RecruitingPhase 4
Returning to HIV Care with Biktarvy
This trial tests the medication Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) for people with HIV who have stopped taking their antiretroviral therapy (ART) for at least 12 weeks and are ready to restart treatment. It aims to see how well the medication works when restarting care.
Clearwater, FloridaAges 18 years+ - NCT07478198Enrolling by invitation
PLLA injections for facial sagging after weight loss drug use
This trial tests whether PLLA injections can safely improve facial sagging in people who lost weight on GLP-1 drugs. If you are between 30 and 60, have noticeable sagging or smile lines, and have not had other facial treatments recently, this may be an option.
Shanghai, Shanghai MunicipalityAges 30–60 - NCT07463599RecruitingPhase 1/Phase 2
Tegavivint for advanced colorectal cancer after other treatments
This early-phase trial tests an experimental drug called tegavivint for people with advanced colorectal cancer who have already tried several standard treatments. It aims to see if the drug can shrink or slow the growth of tumors.
Scottsdale, ArizonaAges 18 years+ - NCT07466238Recruiting
Chemo into the liver plus IV chemo for bile duct cancer
This trial is testing a treatment plan that first delivers chemotherapy directly into the liver (through a thin tube) along with standard IV chemotherapy. The goal is to shrink the tumor enough to allow for surgery or less aggressive treatment later. It is for people with bile duct or gallbladder cancer that has not spread far.
BeijingAges 18–80 - NCT07464756RecruitingPhase 2
Study of SHR-1701 and apatinib with chemo before stomach cancer surgery
This trial tests whether adding SHR-1701 (an immunotherapy) with or without apatinib (a targeted therapy) to standard chemotherapy before surgery can help treat gastric cancer. It is for people with stomach or gastroesophageal junction cancer that has spread to nearby lymph nodes but is still removable.
Nanjing, JiangsuAges 18 years+ - NCT06792162RecruitingPhase 2
Immunotherapy and targeted therapy trial for advanced gastric cancer
This trial tests a combination of two drugs: carilizumab (an immunotherapy) and apatinib (a targeted therapy) for patients with unresectable stage III or IV gastric cancer that has a specific DNA repair problem (dMMR). The goal is to see if this treatment can help shrink tumors and improve outcomes.
BeijingAges 18 years+ - NCT07456696RecruitingPhase 3
TSND-201 for PTSD treatment study
This trial tests if an investigational drug called TSND-201 can help treat PTSD. It is for people who have tried at least one other PTSD treatment before.
Phoenix, ArizonaAges 18 years+ - NCT04449198RecruitingEarly Phase 1
Study for mitochondrial and blood-vessel issues in type 1 diabetes
This early study looks at how a new approach may affect energy-making (mitochondria) and blood-vessel signaling in people with insulin-dependent type 1 diabetes. It may help researchers understand whether these pathways can be improved in type 1 diabetes.
Augusta, GeorgiaAges 18 years+ - NCT07457736RecruitingEarly Phase 1
Testing a new imaging agent for the brain
This study tests a new radioactive dye called [18F]GATT-44 to see how well it can show a specific brain protein on a PET scan. It may help researchers better understand brain conditions in the future.
New Haven, ConnecticutAges 18–60 - NCT07458425Recruiting
Lung cancer screening study using AI
This study tests how well an AI tool can predict lung cancer risk, based on your health information. It looks at how patients feel about this approach to screening, with the goal of making screening more personal and effective.
Chicago, IllinoisAges 50–80 - NCT07444437RecruitingPhase 2
LM103 after surgery for lung cancer
This trial tests if LM103, given after surgery and standard chemotherapy, helps prevent non-small cell lung cancer from coming back. It is for people who have already had chemotherapy or immunotherapy before surgery and whose cancer did not return after surgery.
Guangzhou, GuangdongAges 18–75 - NCT07444203Recruiting
Study of kidney tissue in diabetes-related kidney disease
This study collects and studies kidney tissue (from a biopsy or surgery) from people with diabetes-related kidney disease to learn more about the condition. You may be able to help if you've already had a kidney biopsy or certain kidney surgeries.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05033392RecruitingPhase 2
PD-1 therapy plus chemotherapy before stomach cancer surgery
This Phase 2 trial tests whether adding a PD-1 antibody (JS001/toripalimab) to chemotherapy before surgery can improve outcomes for people with locally advanced stomach or gastroesophageal junction adenocarcinoma. It aims to help shrink the tumor and make surgery more effective.
Shenzhen, GuangdongAges 18–79 - NCT05378490Recruiting
Study of stroke types and thrombolysis treatment
This study includes people who have had certain kinds of sudden brain blood-flow problems (like an ischemic stroke, bleeding in the brain, or a brief warning episode) or conditions that look similar. It looks at how treatment such as clot-busting medicine (thrombolysis) fits for these situations.
LørenskogAges 18 years+ - NCT04886401Recruiting
Study predicting response to pembrolizumab in advanced lung cancer
This study looks back at prior treatment to learn which patients with advanced non-small cell lung cancer (NSCLC) are more likely to respond to pembrolizumab, an immune therapy given up front. The results may help doctors better predict who benefits from this treatment.
BrestAges Any age - NCT06718257Recruiting
Chemo with immunotherapy and targeted drugs for bile duct cancer
This trial tests whether adding immunotherapy and targeted therapy to standard chemotherapy can help treat intrahepatic cholangiocarcinoma (a type of bile duct cancer). It is for patients who are starting treatment with one of two specific chemo regimens, possibly combined with the new drugs.
Hangzhou, ZhejiangAges 18 years+ - NCT07431112RecruitingPhase 1
Study of AIR-001 for adults with alpha-1 antitrypsin deficiency
This study tests an experimental RNA-based medicine (AIR-001) for people with a genetic form of alpha-1 antitrypsin deficiency (AATD). It aims to see if the drug can help boost your body's own protective protein levels and may slow lung damage.
MelbourneAges 18–74 - NCT07428746RecruitingPhase 3
GLP-1 drug for bone health in older women with diabetes
This study tests whether a diabetes medication called a GLP-1 receptor agonist can help improve bone and muscle health in older women with type 2 diabetes who are at risk for osteoporosis. It aims to see if the drug can strengthen bones and prevent falls.
Atlanta, GeorgiaAges 65 years+ - NCT07419854RecruitingPhase 4
Restoring facial fullness after GLP-1 weight loss with Radiesse
This trial tests whether a facial filler called Radiesse can restore volume lost during weight loss from GLP-1 medications (like Wegovy or Mounjaro). It's for adults just starting GLP-1 therapy who expect to lose 20 pounds or more and want to see if fillers can help their face look fuller.
Pasadena, CaliforniaAges 21–65 - NCT07419932Recruiting
Pre-surgery treatment for advanced thyroid cancer
This study tests whether giving treatment before surgery (neoadjuvant therapy) helps people with locally advanced thyroid cancer. It aims to shrink the tumor so surgery can be more successful.
Fuzhou, FujianAges 14–80 - NCT07416890RecruitingPhase 2
Study of thiotepa, pirtobrutinib, and sintilimab for CNS lymphoma
This trial tests a combination of three drugs for people with central nervous system (CNS) lymphoma that has come back or not responded to treatment, or for those who cannot take standard chemotherapy. The goal is to see if this new combination is safe and effective.
Hangzhou, ZhejiangAges 18–80
Common questions
- Are there clinical trials studying S-1?
- Yes. Clin2 currently lists 792 recruiting studies that include S-1, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a S-1 trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is S-1 an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether S-1 or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.